Keywords: Alzheimer's Disease, Alzheimer's Disease, Drug Discovery
Motivation: Anatomical MRI plays an important role in Alzheimer’s Disease drug trials, yet the information it provides may not be fully utilized.
Goal(s): Regional brain volume and its atrophy in conjunction with amyloid- and tau-PET can provide valuable information about disease progression and treatment response.
Approach: Local brain atrophy was quantified and correlated with PET biomarkers.
Results: Significant correlation was reported between atrophy and baseline tau-PET in the medial-temporal region as well as robust associations with disease stage and amyloid burden. These findings can be used to understand disease development and therefore capture modulation in pathology with anti-tau and other therapies in trials.
Impact: Understanding the relationships between brain volumetrics, disease severity and tau burden, including significant correlation between medial-temporal atrophy and tauPET presented in this study allows for efficient measurement of treatment response in AD trials.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords